MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

A

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

Search

Artivion Inc

Cerrado

SectorSalud

43.92 -0.54

Resumen

Variación precio

24h

Actual

Mínimo

43.49

Máximo

45.16

Métricas clave

By Trading Economics

Ingresos

-14M

6.5M

Ventas

416K

113M

Margen de beneficio

5.734

Empleados

1,600

EBITDA

2.6M

19M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+16.7% upside

Dividendos

By Dow Jones

Próximas Ganancias

23 feb 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-100M

2.1B

Apertura anterior

44.46

Cierre anterior

43.92

Noticias sobre sentimiento de mercado

By Acuity

53%

47%

301 / 360 Clasificación en Healthcare

Artivion Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

22 ene 2026, 21:55 UTC

Ganancias

Capital One Financial Posts Higher 4Q Profit As Lending Increases

22 ene 2026, 23:52 UTC

Ganancias

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results and Forecast -- Update

22 ene 2026, 23:48 UTC

Charlas de Mercado

Nikkei May Rise as Tensions Between U.S. and Europe Ease -- Market Talk

22 ene 2026, 23:42 UTC

Charlas de Mercado

Gold Edges Lower on Possible Profit-Taking -- Market Talk

22 ene 2026, 23:40 UTC

Charlas de Mercado

Spark NZ's Market Share Loss Concerns Bear -- Market Talk

22 ene 2026, 23:30 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

22 ene 2026, 23:30 UTC

Charlas de Mercado

Genesis Energy Can Beat Newly Upgraded Earnings Goal -- Market Talk

22 ene 2026, 22:37 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Capital One CEO: Brex Buy Reflects Business Payments Focus -- Market Talk

22 ene 2026, 21:59 UTC

Adquisiciones, fusiones, absorciones

Capital One Strikes $5.15 Billion Deal for Fintech Brex -- Update

22 ene 2026, 21:50 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Tech, Media & Telecom Roundup: Market Talk

22 ene 2026, 21:44 UTC

Ganancias

Self-Driving Stock Mobileye Plunged After Earnings. Here's Why. -- Barrons.com

22 ene 2026, 21:32 UTC

Adquisiciones, fusiones, absorciones

Capital One: Brex Invented Integrated Combination of Corporate Credit Cards, Spend Management Software and Banking in Single Platform >COF

22 ene 2026, 21:31 UTC

Adquisiciones, fusiones, absorciones

Capital One: Brex Is a Modern, AI-native Software Platform Offering Intelligent Finance Solutions >COF

22 ene 2026, 21:31 UTC

Adquisiciones, fusiones, absorciones

Capital One: Franceschi Will Continue to Lead Brex as Part of Capital One >COF

22 ene 2026, 21:30 UTC

Adquisiciones, fusiones, absorciones

Capital One to Acquire Brex in Combination of Stk and Cash Transaction Valued at $5.15 B >COF

22 ene 2026, 21:30 UTC

Ganancias

Intel Returns to Losses as Supply Shortages, Spending Weigh on Q4 Results -- WSJ

22 ene 2026, 21:30 UTC

Adquisiciones, fusiones, absorciones

Capital One To Acquire Brex >COF

22 ene 2026, 21:13 UTC

Ganancias

Intel Returns to Losses in Q4 as It Ramps Up Spending on Chip Production -- WSJ

22 ene 2026, 21:11 UTC

Ganancias

Intuitive Surgical Sees 2026 Impact From Tariffs 1.2% of Revenue, Plus or Minus 10 Basis Points >ISRG

22 ene 2026, 21:11 UTC

Ganancias

Intuitive Surgical Sees 2026 Adjusted Gross Profit Margin 67%-68% >ISRG

22 ene 2026, 21:10 UTC

Ganancias

Intuitive Surgical Sees 2026 Worldwide Da Vinci Procedure Growth of 13%-15% >ISRG

22 ene 2026, 21:06 UTC

Ganancias

Capital One 4Q Total Non-Interest Expense Increased 13% to $9.3B >COF

22 ene 2026, 21:05 UTC

Ganancias

Capital One 4Q Provision for Credit Losses Increased $4.1B >COF

22 ene 2026, 21:05 UTC

Ganancias

Capital One 4Q Rev $15.58B >COF

22 ene 2026, 21:05 UTC

Ganancias

Capital One 4Q EPS $3.26 >COF

22 ene 2026, 21:05 UTC

Ganancias

Capital One 4Q Net Interest Margin 8.26% >COF

22 ene 2026, 21:05 UTC

Ganancias

Capital One 4Q Net $2.13B >COF

22 ene 2026, 21:05 UTC

Ganancias

Capital One 4Q Adj EPS $3.86 >COF

22 ene 2026, 21:05 UTC

Ganancias

Capital One 4Q Net Charge-Offs $3.8B >COF

22 ene 2026, 21:05 UTC

Ganancias

Intuitive Surgical 4Q EPS $2.21 >ISRG

Comparación entre iguales

Cambio de precio

Artivion Inc Esperado

Precio Objetivo

By TipRanks

16.7% repunte

Estimación a 12 meses

Media 51.71 USD  16.7%

Máximo 58 USD

Mínimo 40 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Artivion Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

7 ratings

6

Comprar

1

Mantener

0

Vender

Sentimiento

By Acuity

301 / 360 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura bajista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Artivion Inc

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.
help-icon Live chat